This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Incyte Reports 2012 Fourth-Quarter And Full-Year Financial Results; Provides 2013 Financial Guidance; Updates Shareholders On Key Clinical Programs

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the efficacy or safety of Jakafi, the acceptance of Jakafi in the marketplace, risks related to market competition, the results of further research and development, risks and uncertainties associated with sales, marketing and distribution requirements, risks that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards, the ability to enroll sufficient numbers of subjects in clinical trials, other market or economic factors and technological advances, unanticipated delays, the ability of Incyte to compete against parties with greater financial or other resources, risks associated with Incyte's dependence on its relationships with its collaboration partners, and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended September 30, 2012.

Incyte disclaims any intent or obligation to update these forward-looking statements.

 
INCYTE CORPORATION
Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

   
Three Months Ended Twelve Months Ended

December 31,

December 31,

2012   2011 2012   2011
Revenues:
Product revenues, net $ 43,301 $ 2,012 $ 136,001 $ 2,012
Product royalty revenues 3,652 3,652
Contract revenues 66,737 26,737 156,948 91,948
Other revenues   155     140     458     495  
 
Total revenues   113,845     28,889     297,059     94,455  
 
Costs and expenses:
Cost of product revenues 99 157
Research and development 59,763 51,877 210,391 178,707
Selling, general and administrative 23,729 21,152 85,363 58,219
Other expenses               712  
 
Total costs and expenses   83,591     73,029     295,911     237,638  
 
Income (loss) from operations 30,254 (44,140 ) 1,148 (143,183 )
Interest and other income, net 371 213 764 462
Interest expense   (11,765 )   (11,153 )   (46,058 )   (43,819 )
 
Income (loss) before income taxes 18,860 (55,080 ) (44,146 ) (186,540 )
 
Provision for income taxes   81         174      
 
Net income (loss) $ 18,779   $ (55,080 ) $ (44,320 ) $ (186,540 )
 
Net income (loss) per share
Basic $ 0.14 $ (0.44 ) $ (0.34 ) $ (1.49 )
Diluted $ 0.14 $ (0.44 ) $ (0.34 ) $ (1.49 )

Shares used in computing basic and diluted net income (loss) per share

Basic 131,711 126,388 129,747 125,362
Diluted 139,118 126,388 129,747 125,362
 
 
INCYTE CORPORATION
Condensed Consolidated Balance Sheet Data

(in thousands)

   
December 31, December 31,

2012

2011

 
Cash, cash equivalents, and short-term marketable securities $ 228,418 $ 277,594
Accounts receivable, net 70,951 6,415
Total assets 330,419 328,962
Convertible senior notes(1) 322,043 298,193
Convertible subordinated notes 9,033 17,960
Total stockholders’ deficit (174,957 ) (227,077 )
 

(1) Net of unamortized debt discount of $78.0 million and $101.8 million at December 31, 2012, and December 31, 2011, respectively.

8 of 9

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs